US Pharma MarketingCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechs
Cancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechs is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Parabilis Medicines’ IPO has lived up to the hype—securing $670 million for the largest listing in the biotech sector’s history.
Source: FierceBiotech